With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.

Additional Metadata
Keywords Aged, aging, antineoplastic agent, comorbidity, female, geriatrics, human, large cell lymphoma, male, methodology, monoclonal antibody, oncology, palliative, rituximab
Persistent URL dx.doi.org/10.1007/s11912-008-0063-2, hdl.handle.net/1765/14300
Citation
Lugtenburg, P.J., & Sonneveld, P.. (2008). Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.. Current Oncology Reports (Print), 10(5), 412–419. doi:10.1007/s11912-008-0063-2